devices.longevity.one
Atlas Electroceuticals / Bioelectronic Medicine SCENAR / DENAS — 'Adaptive' Transcutaneous Electroneurostimulation
Electroceuticals / Bioelectronic Medicine

SCENAR / DENAS — 'Adaptive' Transcutaneous Electroneurostimulation

Tested — not confirmedD/EgradePlausibility · Substrate real (TENSElectroceuticals / Bioelectronic Medicine
⚠ Physical risk
Contraindicated in pacemaker wearers, pregnancy, and epilepsy.
tested — not confirmed— Real instrument/substrate; the diagnostic or therapeutic interpretation failed testing; a correct reinterpretation remains open (§0.1-B).

A real TENS-family stimulator whose specific 'adaptive' (skin-resistance-tuned) advantage was tested and not shown: in a single-blind RCT, pain fell equally with the device on and off. The substrate — ordinary neurostimulation — is real; the adaptive claim, and the broad disease programs sold around it, are not. This record exists because the brand was riding the TENS class grade.

Origin & lineage
Karasev, USSR, 1970s (developed for cosmonauts); RITM (SCENAR), DENAS.
Claimed mechanism
Skin-impedance-'adaptive' biofeedback electrostimulation, claimed to act across pain plus broad disease programs (allergy, hypertension, 'cancelled joint replacements', Lyme).
Plausibility
Substrate real (TENS-family current); the 'adaptive' advantage was tested and not shown; the broad disease claims are unstudied.
Evidence — grade D/E
Single-blind RCT (J Clin Med 2021, n=60): Scenar-On group = Scenar-Off (sham) group — pain fell equally in both. Registered as a TENS device (Australia ARTG), so the substrate is real. Broad disease programs are unstudied, kept in a separate claims-vs-evidence block, not demonstrated.
Market
Makers: RITM (SCENAR); DENAS.
Models: SCENAR; DENAS.
Price: ~$150–2,500.

Kernel — keep vs set aside

Keep — real substrate
It is a genuine TENS-family stimulator — ordinary, dosed neurostimulation is real, and has a modest evidence base for pain (see the TENS record).
Set aside — claim
The 'adaptive' skin-resistance advantage failed a single-blind RCT (active = sham). The systemic disease programs are unstudied, not demonstrated.

Regulatory status by jurisdiction

Registration or clearance is a market-access fact, never proof of efficacy.

US — FDASCENAR Class II 510(k) for pain (2010); systemic claims FTC-actionable.
EU — MDRCE marked (electrostimulation).
RussiaMoH registered (SCENAR / DENAS).
China — NMPANot found.
Australia — TGAARTG-listed as a TENS device.

Sources